Compounds > 20-hydroxy-5,8,11,14-eicosatetraenoic acid
Page last updated: 2024-09-03

20-hydroxy-5,8,11,14-eicosatetraenoic acid and Vascular Diseases

20-hydroxy-5,8,11,14-eicosatetraenoic acid has been researched along with Vascular Diseases in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Edin, ML; Garcia, V; Hoopes, SL; Schwartzman, ML; Zeldin, DC1
Benter, IF; Yousif, MH1
Chen, K; Croft, KD; Keaney, JF; Li, C; Ward, NC1
Falck, JR; Lombard, JH; Lukaszewicz, KM; Manthati, VL1
Akhtar, S; Benter, IF; Canatan, H; Yousif, MH1

Reviews

1 review(s) available for 20-hydroxy-5,8,11,14-eicosatetraenoic acid and Vascular Diseases

ArticleYear
Vascular actions of 20-HETE.
    Prostaglandins & other lipid mediators, 2015, Volume: 120

    Topics: Animals; Blood Vessels; Humans; Hydroxyeicosatetraenoic Acids; Neovascularization, Physiologic; Renin-Angiotensin System; Vascular Diseases; Vascular Remodeling

2015

Other Studies

4 other study(ies) available for 20-hydroxy-5,8,11,14-eicosatetraenoic acid and Vascular Diseases

ArticleYear
Role of 20-hydroxyeicosatetraenoic and epoxyeicosatrienoic acids in the regulation of vascular function in a model of hypertension and endothelial dysfunction.
    Pharmacology, 2010, Volume: 86, Issue:3

    Topics: Amidines; Animals; Arachidonic Acids; Blood Pressure; Carbachol; Cardiovascular Physiological Phenomena; Carotid Arteries; Endothelial Cells; Hydroxyeicosatetraenoic Acids; Hypertension; Male; Norepinephrine; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Urea; Vascular Diseases; Vasoconstriction; Vasoconstrictor Agents; Vasodilation

2010
Chronic activation of AMP-activated protein kinase prevents 20-hydroxyeicosatetraenoic acid-induced endothelial dysfunction.
    Clinical and experimental pharmacology & physiology, 2011, Volume: 38, Issue:5

    Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Aorta; Cells, Cultured; Cytoprotection; Drug Evaluation, Preclinical; Endothelium, Vascular; Enzyme Activators; Humans; Hydroxyeicosatetraenoic Acids; Male; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase Type III; Phosphorylation; Proto-Oncogene Proteins c-akt; Ribonucleotides; Time Factors; Vascular Diseases; Vasoconstrictor Agents

2011
Introgression of Brown Norway CYP4A genes on to the Dahl salt-sensitive background restores vascular function in SS-5(BN) consomic rats.
    Clinical science (London, England : 1979), 2013, Volume: 124, Issue:5

    Topics: Animals; Blood Pressure; Cerebral Arteries; Cytochrome P-450 CYP4A; Endothelium, Vascular; Hydroxyeicosatetraenoic Acids; Male; Muscle, Smooth, Vascular; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Rats; Rats, Inbred BN; Rats, Inbred Dahl; Reactive Oxygen Species; Superoxide Dismutase; Vascular Diseases; Vasodilation

2013
Inhibition of Ca2+/calmodulin-dependent protein kinase II, RAS-GTPase and 20-hydroxyeicosatetraenoic acid attenuates the development of diabetes-induced vascular dysfunction in the rat carotid artery.
    Pharmacological research, 2005, Volume: 52, Issue:3

    Topics: Amidines; Animals; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Carotid Arteries; Carotid Artery Diseases; Diabetes Mellitus, Experimental; Hydroxyeicosatetraenoic Acids; Monomeric GTP-Binding Proteins; Organophosphonates; Protein Kinase Inhibitors; Rats; Rats, Wistar; Streptozocin; Sulfonamides; Triazoles; Vascular Diseases; Vasoconstriction; Vasodilation

2005